Show simple item record

dc.contributor.authorLin, Y.
dc.contributor.authorLeng, Q.
dc.contributor.authorZhan, M.
dc.date.accessioned2019-04-29T19:00:59Z
dc.date.available2019-04-29T19:00:59Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85051062213&doi=10.1016%2fj.tranon.2018.07.016&partnerID=40&md5=ae37f184e73e61efff4fed9815ecc28f
dc.identifier.urihttp://hdl.handle.net/10713/8919
dc.description.abstractThe early detection of lung cancer is a major clinical challenge. Long noncoding RNAs (lncRNAs) have important functions in tumorigenesis. Plasma lncRNAs directly released from primary tumors or the circulating cancer cells might provide cell-free cancer biomarkers. The objective of this study was to investigate whether the lncRNAs could be used as plasma biomarkers for early-stage lung cancer. By using droplet digital polymerase chain reaction, we determined the diagnostic performance of 26 lung cancer-associated lncRNAs in plasma of a development cohort of 63 lung cancer patients and 33 cancer-free individuals, and a validation cohort of 39 lung cancer patients and 28 controls. In the development cohort, 7 of the 26 lncRNAs were reliably measured in plasma. Two (SNHG1 and RMRP) displayed a considerably high plasma level in lung cancer patients vs. cancer-free controls (all P < .001). Combined use of the plasma lncRNAs as a biomarker signature produced 84.13% sensitivity and 87.88% specificity for diagnosis of lung cancer, independent of stage and histological type of lung tumor, and patients' age and sex (all P > .05). The diagnostic value of the plasma lncRNA signature for lung cancer early detection was confirmed in the validation cohort. The plasma lncRNA signature may provide a potential blood-based assay for diagnosing lung cancer at the early stage. Nevertheless, a prospective study is warranted to validate its clinical value. Copyright 2018 The Authorsen_US
dc.description.sponsorshipGrant support: This work was supported in part by NCI R21CA205746 , VA Merit Award I01 CX000512 , Award from the Geaton and JoAnn DeCesaris Family Foundation , UMD-UMB Research and Innovation Seed Grant , DoD-Idea Development Award , and Maryland Innovation Initiative (MII) Commercialization Program-Phase 1/2 Grant (F.J.)en_US
dc.description.urihttps://dx.doi.org/10.1016/j.tranon.2018.07.016en_US
dc.language.isoen_USen_US
dc.publisherNeoplasia Press, Inc.en_US
dc.relation.ispartofTranslational Oncology
dc.subjectRNA, Long Untranslateden_US
dc.subjectNeoplasmsen_US
dc.subjectcancer tissuesen_US
dc.titleA Plasma Long Noncoding RNA Signature for Early Detection of Lung Canceren_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.tranon.2018.07.016


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record